HOME >> BIOLOGY >> NEWS
Treatment extends survival in mouse model of spinal muscular atrophy

Drug therapy can extend survival and improve movement in a mouse model of spinal muscular atrophy (SMA), new research shows. The study, carried out at the NIHs National Institute of Neurological Disorders and Stroke (NINDS), suggests that similar drugs might one day be useful for treating human SMA.

"This study shows that treatment can be effective when started after the disease appears," says Kenneth H. Fischbeck, M.D., of the NINDS, who helped lead the new study. The finding is important because most children with SMA are diagnosed after symptoms of the disease become obvious, he adds. The report appears in the February 22, 2007, advance online publication of The Journal of Clinical Investigation.*

SMA is the most common severe hereditary neurological disease of childhood, affecting one in every 8,000-10,000 children. Babies with the most common form of the disease, called SMA type I, develop symptoms before birth or in the first few months of life and have severe muscle weakness that makes it difficult for them to breathe, eat, and move. They usually die by age two. Other forms of SMA are not as severe, but still cause significant disability. While some symptoms of SMA can be alleviated, there is currently no treatment that can change the course of the disease.

SMA is caused by mutations in a gene called SMN1. Investigators studying the genetics of SMA have found that there is another gene, called SMN2, on the same chromosome. While the normal form of SMN1 produces a full-length functional protein, most of the protein produced by SMN2 is truncated and unable to function. The relatively small amount of normal SMN protein produced by the SMN2 gene can reduce the severity of the disease. Therefore, investigators are searching for drugs that can increase the amount of normal protein produced by this gene.

The new study, directed by Dr. Fischbeck's colleague Charlotte J. Sumner, M.D., at NINDS, tested a drug called trichostatin A
'"/>

Contact: Natalie Frazin
301-496-5924
NIH/National Institute of Neurological Disorders and Stroke
22-Feb-2007


Page: 1 2 3

Related biology news :

1. Treatment-induced growth factor causes cancer progression
2. Water Treatment and Reuse -- II
3. Treatments for urinary infections leave bacteria bald, happy and vulnerable
4. Treatment disconnect in kidney cancer: Rising mortality despite more small tumors, more surgery
5. Evolving Issues in the Prevention and Treatment of Influenza: A media forum
6. NHLBI media availability: Treatment shows long-term benefits for cystic fibrosis patients
7. Treatments have same target, different responses for lung cancer patients with genetic mutation
8. Back to the future: Mastodon extends the time limit on DNA sequencing
9. Wiley extends publishing partnership with the American Institute of Chemical Engineers
10. Nexavar significantly extends overall survival by 44 percent in liver cancer patients
11. Vitamin extends life in yeast, Dartmouth Medical School researchers find

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2020)... (PRWEB) , ... August 06, 2020 , ... ... sciences industry, is pleased to announce that Eric Chen and Jessica Wong have ... of Product Management & Strategy, respectively. , Eric Chen heads development efforts for ...
(Date:7/31/2020)... (PRWEB) , ... July 30, 2020 , ... ... prescription digital therapeutics product portfolio with a near term focus on Type 2 ... and pharma commercialization experience across multiple therapeutic areas and classes. As Chief Commercial ...
(Date:7/10/2020)... ... July 09, 2020 , ... Today CJ BIO announced ... will share insight on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, nutritional ... Advantage will be live on Monday, July 13, 2020 at11:00 AM (CDT) during SHIFT20, ...
Breaking Biology News(10 mins):
(Date:8/15/2020)... , ... August 13, 2020 , ... True Terpenes ... creation of its Scientific Advisory Board (SAB) to research the medical potential of terpenes ... be enhanced when combined with terpenes. The board is focused on expanding the recently ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... firm, is making available for free its new white paper – Simulated ... simulation testing into today’s biologics licensing application (BLA). In response, Modality Solutions ...
(Date:8/3/2020)... ... August 03, 2020 , ... ... Jim Corrigan, President and CEO has been named one of the 100 most ... industry sectors, PharmaVoice 100 honorees are selected based on how they have inspired ...
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON ... of its new tagline, “BUILDING FOR LIFE.” The adoption of this taglines comes ... globe, requiring fast track capacity to provide patients with urgently needed vaccines and ...
Breaking Biology Technology:
Cached News: